Macrophage inflammatory protein 1alpha attenuates the toxic effects of temozolomide in human bone marrow granulocyte-macrophage colony-forming cells.
Watson, Amanda J
Heyworth, Clare M
Lord, Brian I
Testa, Nydia G
Dexter, T Michael
Margison, Geoffrey P
AffiliationCancer Research Campaign Department of Medical Oncology, Manchester, United Kingdom. firstname.lastname@example.org
MetadataShow full item record
AbstractMacrophage inflammatory protein 1alpha (MIP-1alpha) is a chemokine that may act principally by preventing hemopoietic cells from entering G1, thereby attenuating the cytotoxic effects of cell cycle-specific chemotherapeutic agents. Here we examine the effect of MIP-1alpha on the sensitivity of human granulocyte-macrophage hemopoietic progenitor cells (granulocyte-macrophage colony-forming cells; GM-CFCs) with the cytotoxic effects of antitumor agents that act mainly via alkylation at the O6 position of guanine in DNA. Mononuclear cell preparations from human bone marrow were used in an in vitro GM-CFC colony-forming assay. The GM-CFC survival from individual patients displayed a range of sensitivities to the methylating agent temozolomide [(Tz) 20-55% survival at 10 microg/ml Tz]. However, in all 16 cases, MIP-1alpha (50 ng/ml) protected against GM-CFC killing: survival in the presence of MIP-1alpha ranged from 65-97% at 10 microg/ml Tz, with GM-CFCs being 1.5-4.5-fold more resistant than control cells from the same patient. The highest levels of protection were seen in the GM-CFCs with the highest sensitivity in the absence of MIP-1alpha. Similar degrees of protection were seen for the methylating agent streptozotocin, but no protection was detected for the chloroethylating agents carmustine or mitozolomide in the samples for which there was protection against the toxic effects of Tz. Whereas the mechanism of this effect remains to be established, the results may have potential immediate clinical application in the attenuation of hematological toxicity after administration of methylating antitumor agents.
CitationMacrophage inflammatory protein 1alpha attenuates the toxic effects of temozolomide in human bone marrow granulocyte-macrophage colony-forming cells. 2000, 6 (3):966-70 Clin. Cancer Res.
JournalClinical Cancer Research
- Differential response of CD34+ cells isolated from cord blood and bone marrow to MIP-1 alpha and the expression of MIP-1 alpha receptors on these immature cells.
- Authors: de Wynter EA, Durig J, Cross MA, Heyworth CM, Testa NG
- Issue date: 1998
- Macrophage inflammatory protein 1alpha enhances in a different manner adhesion of hematopoietic progenitor cells from bone marrow, cord blood, and mobilized peripheral blood.
- Authors: Suehiro Y, Muta K, Umemura T, Abe Y, Nishimura J, Nawata H
- Issue date: 1999 Nov
- [Protection of hematopoietic stem cells by MIP-1alpha and PF4 against the cytotoxicity of chemotherapeutic agents].
- Authors: Huang K, Huang S, Pan J, Wu Y
- Issue date: 2000 Jul
- Inhibition of immature erythroid progenitor cell proliferation by macrophage inflammatory protein-1alpha by interacting mainly with a C-C chemokine receptor, CCR1.
- Authors: Su S, Mukaida N, Wang J, Zhang Y, Takami A, Nakao S, Matsushima K
- Issue date: 1997 Jul 15
- Enhancing hemopoietic drug resistance: a rationale for reconsidering the clinical use of mitozolomide.
- Authors: Fairbairn LJ, Chinnasamy N, Lashford LS, Chinnasamy D, Rafferty JA
- Issue date: 2000 Feb